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A Second Locus for Very-Late-Onset Alzheimer Disease: A Genome Scan
Reveals Linkage to 20p and Epistasis between 20p and the Amyloid
Precursor Protein Region
Jane M. Olson, Katrina A. B. Goddard, and Doreen M. Dudek
Department of Epidemiology and Biostatistics, Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve
University, Cleveland, OH
We used a covariate-based linkage method to reanalyze genome scan data from affected sibships collected by the
Alzheimer Disease (AD) Genetics Initiative of the National Institute of Mental Health. As reported in an earlier
article, the amyloid-b precursor protein (APP) region is strongly linked to affected sib pairs of the oldest current
age (i.e., age either at last exam or at death) who lack E4 alleles at the apolipoprotein E (ApoE) locus. We now
report that a region on 20p shows the same pattern. A model that includes current age and the number of E2
alleles as covariates gives a LOD score of 4.1. The signal on 20p is near the location of the gene coding for cystatin-
C, previously shown to be associated with late-onset AD and to codeposit with APP in the brains of patients with
AD. Two-locus analysis provides evidence of strong epistasis between 20p and the APP region, limited to the oldest
age group and to those lacking ApoE4 alleles. We speculate that high-risk polymorphisms in both regions produce
a biological interaction between these two proteins that increases susceptibility to a very-late-onset form of AD.
Alzheimer disease (AD) is the most common form of de-
mentia in the elderly and is believed to be genetically
complex. To date, three genetic loci have been identified
that contribute to early-onset autosomal dominant AD:
presenilin 1 (PSEN1 [MIM104311]), presenilin 2 (PSEN2
[MIM 633044]), and amyloid-b precursor protein (APP
[MIM 104760]). However, only apolipoprotein E (ApoE
[MIM 107741]) has been well-established as contributing
to late-onset AD (see, e.g., Corder et al. 1993; Saunders
et al. 1993). Daw et al. (2000) found evidence formultiple
genetic loci contributing to the age at onset of AD with
effect sizes similar to or larger than the effect of the ApoE
locus, suggesting a role of additional genetic-risk factors
in the age at onset of AD. However, clear evidence of
additional loci that contribute to risk or age at onset has
remained elusive, although substantial linkage evidence
exists for regions on chromosomes 9 (Pericak-Vance et al.
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1997), 10 (Bertram et al. 2000; Ertekin-Taner et al. 2000;
Myers et al. 2000), and 12 (Pericak-Vance et al. 1997).
Locus heterogeneity, such as may be present for late-
onset AD, presents a challenge in the analysis and in-
terpretation of linkage results. Recently, we developed a
model-free linkage method that allows covariates to be
included in the analysis (Goddard et al. 2001). This
method accounts for locus heterogeneity that is mea-
sured by covariates, thereby allowing the discovery of
evidence for linkage that might otherwise be obscured.
We have demonstrated the potential effectiveness of this
method in a recent analysis of the APP region, using
affected sib pairs (ASPs) collected as part of the National
Institute of Mental Health (NIMH) AD Genetics Initia-
tive (Olson et al. 2001). In the case of the APP region,
we observed an increase in the LOD score from .04 to
5.54 after we included current age as a covariate in the
linkage model. Our results indicated that the families
with AD that have the oldest current age and no ApoE4
alleles exhibit linkage to APP.
In the present study, we revisit the data collected by
the NIMH AD Genetics Initiative and analyze the re-
maining autosomes through use of the same covariate-
based method of ASP linkage analysis. We chose, as
covariates, variables that we believed were likely to be
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Table 1
Descriptive Statistics of Variables and Covariates
Variable/Covariate Mean SD Range
Within-Pair
Correlation
Original Variable:a
Age at onset (years) 74.77 5.84 61–93
Current age (years) 83.33 6.72 63–105
ApoE allele frequencies:
E2 .024
E3 .581
E4 .395
Covariate:b
Age at onset (years) 149.18 9.88 127–181 .37
Current age (years) 166.37 11.81 134–208 .55
No. of E4 alleles 1.62 1.13 0–4 .58
No. of E2 alleles .08 .32 0–2 .25
Current age (years):
0 E4 alleles ( )N p 56 175.02 11.50 154–208
1 E4 allele ( )N p 56 167.13 11.55 143–192
2 E4 alleles ( )N p 114 165.12 9.97 141–190
3 E4 alleles ( )N p 27 159.19 10.71 134–179
4 E4 alleles ( )N p 19 156.32 8.42 144–169
a sibs.N p 461
b ASPs. Statistics are for the sum of the pair’s values beforeN p 272
centering. Covariates were centered before inclusion in linkagemodels.
related to locus heterogeneity. Specifically, we examine
the roles that age at onset, current age (age at last exam
or age at death), and ApoE genotype play in linkage
heterogeneity to late-onset AD. As we shall see, we find
substantial evidence for linkage on 20p, in addition to
the signal in the APP region that we reported previously.
We also present an extension of our linkage analysis
method to include two-locus models, to examine a pos-
sible epistatic interaction between the signal in the APP
region and the new signal on 20p.
The collection, characterization, and genotyping of
AD-affected sibships by the NIMH AD Genetics Initia-
tive has been previously described (Blacker et al. 1997).
We restricted our analysis to 272 ASPs that had onset
at age 60 and also had complete data on the following
variables: age at onset (as measured by age at first symp-
toms), current age (as measured by either age at last
exam [33%] or age at death [67%]), and ApoE geno-
type. The lower bound on age at onset was imposed to
eliminate the possible effect of outliers on the linkage
analysis; only four ASPs were removed for this reason.
For age at onset and current age, the covariate included
in the linkage analysis was the sum of the values of the
two individuals. For ApoE genotype, we considered two
covariates: (1) the total number of E4 alleles in the ASP
and (2) the total number of E2 alleles in the ASP. Mul-
tipoint identity-by-descent values were computed at 2-
cM intervals throughout the genome, by use of all mark-
ers available from the genome scan.
To allow for covariate-related locus heterogeneity, we
applied a covariate-based ASP LOD-score method (God-
dard et al. 2001) to the genotype data. The model is a
one-parameter modification of the conditional logistic
parameterization of the ASP LOD score introduced by
Olson (1999). An optimal mode of inheritance param-
eter (Whittemore and Tu 1998) is specified that allows
one to fit only a single additional parameter per covar-
iate. The model is parameterized in terms of offspring
recurrence-risk ratio (l1), conditional on K covariates
, asxk
K
l (x) p exp b g x , (1)1 k k( )
kp1
where b is a parameter that measures the “average”
linkage in the sample and the are covariate-specificgk
parameters that measures the change in linkage as a
function of the covariates, and in terms of the recur-
rence-risk ratio for monozygotic twins ( ), conditionall2
on K covariates , asxk
l (x) p 3.634l (x) 2.634 . (2)2 1
This model has been implemented in the S.A.G.E. pro-
gram LODPAL.
To simplify specification of constraints on parameter
estimates, to improve numerical stability, and so that b
reflects average allele-sharing, all covariates are centered
around their sample mean before they are included in
the linkage model. Because covariates are centered
around their mean, inclusion of a covariate in the model
is not expected to give a different value of b than that
estimated in the model without covariates, unless the
distribution of the covariate is asymmetric, as is the case
with the number of E4 alleles. In general, the values of
b and the depend on the choice of “coding scheme”gk
for the covariates; a linear transformation of the covar-
iate does not change either the LOD score or the esti-
mates of covariate-specific recurrence-risk ratios. More
importantly, conclusions about the existence of locus
heterogeneity and the extent or nature of locus hetero-
geneity do not depend on the estimated value of b (which
may equal zero).
Asymptotic distributions of the resulting likelihood-
ratio tests were used to obtain P values (see Goddard et
al. 2001). In the present study, we report as “LOD”
scores the likelihood-ratio statistics (LRSs) divided by
4.605 (i.e., 2loge10). Critical values for the LRSs were
obtained as follows. The distribution of the LRS for the
basic one-parameter model is a 50:50 mixture of a point
mass at zero and a x2 distribution with 1 df. Addition
of K covariates gives an LRS with a distribution that is
a 50:50 mixture of a x2 with K df and a x2 with K
df. The difference in LRS between nested models that1
differ by J covariates has a x2 distribution with J df. One
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Figure 1 Genome scan results for baseline (without covariates) and single-covariate models. A LOD score of 2.1 correponds to the
significance level for the baseline model; a LOD score of 2.8 corresponds to the the significance level for models with aa p .001 a p .001
single covariate.
can therefore test both the significance of the contri-
bution of a covariate and the overall evidence for link-
age. The overall evidence for linkage includes infor-
mation about both the “average” linkage for the sample
and the change in linkage as a function of the covariate.
Two-locus models were used to examine regions dem-
onstrating linkage for possible interaction, conditional
on one or more covariates. First, let be the recur-l (x)ij
rence-risk ratio corresponding to the sharing of i alleles
at the first locus and j alleles at the second locus, for
, conditional on covariates as in equationi,j p 0,1,2 xk
(1)—that is,
l (x) p exp b  g x ,kij ij ijk k( )
where and are the corresponding “average” andb gij ijk
covariate-specific linkage parameters, respectively. An
extension of equation (2) to two loci gives the con-
straints andl (x) p 3.634l (x) 2.634l (x) l (x) pi2 i1 i0 2j
, subject to . The3.634l (x) 2.634l (x) l (x) { 11j 0j 00
model without covariates has three free parameters: two
“single-locus” parameters, andb p log (l ) b p10 e 10 01
, and the joint (two-locus) parameter,log (l ) b pe 01 11
. As many as three parameters for each covariatelog (l )e 11
may be added, one for each risk ratio. Likelihood-ratio
statistics then can be used to compare nested models. In
addition, a model additive in penetrance (to approximate
a heterogeneity model) was fitted by putting l (x) pij
, and a model multiplicative in pene-(1) (2)l (x) l (x) 1i j
trance was fitted by putting , for(1) (2)l (x) p l (x)l (x)ij i j
(see Risch 1990; Olson 1999). In these ex-i,j p 0,1,2
pressions, represents a risk-ratio–like quantity spe-(l)l (x)i
cific to locus l, for . In the absence of covariates,l p 1,2
these two models each contain two free parameters, one
for each of the two loci; as many as two parameters per
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Table 2
LOD Scores, Parameter Estimates, and Significance Levels for Baseline and Single Covariate
Models
Nearest Marker
(Distance from
First Marker,
in cM)
Baseline
LOD
Scorea Covariate
Overall LOD
Score (P)b b g
LOD-Score
Difference (P)c
D1S1675 (172) 1.21 … 1.21 (.0091) .16 … …
D5S1470 (46) 1.01 E4 2.03 (.0058) .18 .15 1.02 (.0302)
D6S1007 (188) 3.88 … 3.88 (.000012) .36 … …
D9S176 (106) 1.06 E4 2.58 (.0016) .17 .16 1.52 (.0082)
D10S1211 (62) 2.13 … 2.13 (.00087) .28 … …
D11S2002 (78) 1.18 … 1.18 (.0099) .16 … …
D14S72 (0) .30 E4 1.92 (.0075) .09 .16 1.62 (.0063)
D14S1015 (90) .00 Age at onset 1.89 (.0080) .00 .02 1.89 (.0032)
D19S571 (80) 1.95 E4 3.10 (.0005) .26 .17 1.15 (.0214)
D20S186 (24) .00 Current age 2.69 (.0012) .00 .01 2.69 (.0004)
D21S1435 (30) .03 Current age 5.91 (.0000007) .11 .03 5.88 (.0000002)
a LOD score for the model without covariates.
b LOD score and associated P value for the model with one covariate.
c Difference in LOD scores and associated P value between the baseline and overall models, giving
the LOD score for the effect on linkage of the covariate.
covariate may be added, in a manner similar to equation
(1).
Table 1 contains descriptive statistics for the variables
used to construct covariates for the linkage analysis. The
covariates were included in the model as the sum of the
values for the two individuals comprising each ASP; ta-
ble 1 also includes the mean and SD for these covariates
as well as for the original variables. Ages at onset for
individuals in this study ranged from 61 to 93 years,
with a mean of 74.8 years. As expected, there was a
higher frequency of E4 alleles (0.395) than in the general
population. We also noted a monotonic increase in cur-
rent age as the number of E4 alleles decreased.
Figure 1 shows genome-scan results for the baseline
model and single-covariate models with age at onset,
current age, and E4 as covariates. Regions in which the
total LOD score was significant at the .01 level are given
in table 2. The largest single-covariate signal is on chro-
mosome 21; a more detailed analysis of this region is
presented by Olson et al. (2001) and will not be repeated
here. For the baseline model (i.e., without covariates),
five regions are significant at the .01 level (table 2), in-
cluding the ApoE region; the highest LOD score is at
the last marker on chromosome 6. Of the five regions
with significant baseline effects, four (chromosomes 1,
6, 10, and 11) show no significant effect of any covariate
at the .05 level. The remaining region (chromosome 19)
shows evidence that ASPs with more E4 alleles are more
likely to be linked. Three additional regions (chromo-
somes 5, 9, and 14) show little or no linkage when the
baseline model is used but do show some effect of E4;
for these three regions, ASPs with more E4 alleles are
more likely to be linked.
Of the regions significant at the .01 level that also
show an E4 effect, only one is in a region containing a
strong candidate locus: the region on chromosome 19
that contains the ApoE locus itself. It has long been
known that E4 is a risk factor for late-onset AD, and
these results are consistent with previous findings. The
addition of E2 to the E4 model on chromosome 19 gives
a significant increase in the LOD score, to 4.03 (P p
for E2 effect). Therefore, the best, most parsi-.0385
monious model contains E2 and E4 ( ,b p .304 g pE2
, ), indicating increasing evidence for.323 g p .222E4
linkage with decreasing numbers of E2 alleles and in-
creasing numbers of E4 alleles.
Three chromosomal regions showed significant evi-
dence for linkage at the .01 level when either current
age or age at onset was included in the model (table 2).
We followed up the age-at-onset peak (LOD score p
1.89) on chromosome 14, which is ∼15 cM distal to
PSEN1, one of the genes linked to early-onset AD (Sher-
rington et al. 1995). Multiple regression analysis failed
to increase the LOD score significantly, and no substan-
tial evidence of linkage for any model was found at 74
cM, the approximate location of PSEN1. In the process
of fitting these models, however, we did observe a LOD
score of 4.14 ( ) at 60 cM (between D14S63P p .00051
and D14S43, ) when E2 ( ), E4b p .056 g p .511
( ), and age at onset ( ) were used asg p .038 g p .011
covariates. ASPs with more E4 alleles, fewer E2 alleles,
and earlier age at onset are most strongly linked.
Excluding chromosome 21, the largest effect for a sin-
gle covariate was for current age, on chromosome 20
(LOD scorep 2.69). Since smaller effects were observed
at this location for E2 and E4, we followed up with
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Table 3
LOD Scores, Parameter Estimates, and Significance Levels for Chromosome 20 at 24 cM
Model LOD Score (Overall P) b g1 g2 g3
LOD-Score Difference
from Nearest Model (P)
Baseline .00 (1.0000) .00 …
ApoE4 (E4) 1.01 (.0644) .00 .11 1.01 (.0310)
ApoE2 (E2) 1.59 (.0163) .00 .77 1.59 (.0068)
E4E2 2.19 (.0122) .00 .08 .69 .60 (.0965)
Age at onset .85 (.0946) .00 .01 .85 (.0479)
Current age (C) 2.69 (.0012) .00 .01 2.69 (.0004)
CE2 4.09 (.0002) .00 .01 .58 1.41 (.0108)
CE2E4 4.11 (.0005) .00 .01 .58 .01 .02 (.7615)
NOTE.—Boldface italics indicate the best, most-parsimonious model.
multiple regression analyses (table 3). The best, most-
parsimonious model includes both current age and E2;
ASPs most likely to be linked are those with the oldest
current age who have E2 alleles. The large difference in
LOD score between the model with age at onset (LOD
score p 0.85) and the model with current age (LOD
score p 2.69) suggests that an analysis with only age
at onset would not have detected this region. Although
the correlation between current age and age at onset is
expected to be high, we note that there is a higher within-
pair correlation for current age (0.55) than for age at
onset (0.37). The meaning of the current age covariate
is unclear, although the difference in the LOD scores
suggests that this locus more likely influences disease
progression, since current age equals age at onset plus
disease duration (Olson et al. 2001).
Our final model for chromosome 20 closely resembles
the model previously reported for the APP region on
chromosome 21 (Olson et al. 2001). Both locations
show that the likelihood of linkage increases with in-
creasing current age and with increasing number of E2
alleles and decreasing number of E4 alleles. Although
the final models differ somewhat in their details (for
example, the APP region shows no effect of ApoE once
current age is accounted for), the striking similarities
suggest the possibility that the same subset of families
segregates for disease alleles in both locations. For that
reason, we fit two-locus models to determine whether
epistasis could be detected statistically.
Table 4 gives some results of this analysis. Because of
computational difficulties in fitting a full model with
both current age and E2, we begin with a full model
with only current age as a covariate. This full model
gives a LOD score of 12.74, which differs significantly
from the two single-locus models, the multiplicative
model, and the heterogeneity model. A more parsimo-
nious model is obtained by allowing only the joint re-
currence-risk ratio l11 to depend on current age (LOD-
score difference p 1.08; , 2 df). The additionP p .083
of E2 to l11 increases the LOD score by .96 (P p
, 1 df) to 12.62, but the further addition of E2 to.036
the “single-locus” recurrence-risk ratios l01 and l10 gives
no further improvement ( , 2 df). We concludeP p .339
that the best, most parsimonious model includes the co-
variates only in the joint recurrence-risk ratio and further
note that, in this model, the “single-locus” estimates of
b equal zero. According this model, ASPs who share no
alleles IBD at one or both loci contribute no linkage
evidence (i.e., for and all valuesl (x) p 1 i,j p 0,1,2ij
of x); only ASPs who share at least one allele IBD at
both loci contribute linkage evidence, with the most
strongly linked pairs being those of the oldest age and,
to a lesser extent, those with the most E2 alleles.
We thus obtained strong evidence for linkage to chro-
mosome 20p (a location different from the signal in
20q13 detected by Pericak-Vance et al. [1997]). One
candidate gene, located at 20p11.2, is cystatin C (CST3
[MIM 119817]), a cysteine protease inhibitor involved
in hereditary cerebral hemorrhage with amyloidosis–
Icelandic type (HCHWA-I) (Levy et al. 1989). The CST3
locus is ∼15 cM proximal to our peak location. Evidence
of genetic association between late-onset AD and aCST3
polymorphism has been described in three case-control
studies (Crawford et al. 2000; Finckh et al. 2000; Beyer
et al. 2001); all three showed that the strength of this
association increased with increasing age. Their results
are consistent with our finding that linkage is strongest
in the oldest ASPs and, to a lesser extent, in those with
E2 alleles. As discussed by Olson et al. (2001), it may
be that the effect of ApoE is the result of attrition due
to the detrimental effects of E4 at earlier ages. Beyer et
al. (2001) also observed an association in the earlier-
onset subset and argued that CST3 interacts with ApoE
at earlier ages. This conclusion was based on results from
a very small portion of their data and is not supported
by our finding of lack of linkage to 20p at earlier ages.
No association with CST3 was found in a Japanese sam-
ple (Maruyama et al. 2001), and no linkage to CST3
was found in eight extended families with mean ages at
onset of 36–65 years (Parfitt et al. 1993).
We also report evidence for strong epistasis between
the 20p region and the region of the APP locus. Our
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Table 4
Two-Locus Models for 20p and 21p (the APP Region)
MODEL
LOD
Score P
PARAMETER ESTIMATE
20p 21p Interaction
b gage gE2 b gage gE2 b gage gE2
With current age:
20p 2.69 !.00001a .00 .01 … … … … … … …
21p 5.91 !.00001a … … … .11 .03 … … … …
Multiplicative 8.60 .00004a .00 .01 … .11 .03 … … … …
Heterogeneity 8.37 .00003a .00 .01 … .04 .02 … … … …
No single-locus age 11.66 .083a .06 … … .12 … … .04 .03 …
Full 12.74 … .00 .01 … .09 .01 … .12 .02 …
With age and E2:
No single-locus E2 12.62 .0355b .00 … … .00 … … .10 .02 .29
Full E2 13.09 .3389c .02 … .46 .00 … .00 .10 .02 .38
NOTE.—Boldface italics indicate the best, most-parsimonious model.
a Compared with full model.
b Compared with no single-locus age.
c Compared with no single-locus E2.
results indicate that a subset of families with AD seg-
regates for susceptibility loci at both locations and sug-
gest that susceptibility alleles at both loci must be present
for AD to occur. In patients with AD, CST3 has been
shown to be codeposited with amyloid-b in amyloid
plaques in the brain (Levy et al. 2001), as well as co-
localized with amyloid-b in brain arteriolar walls (Vin-
ters et al. 1990). In the rare autosomal dominant disease
HCHWA-I, a point mutation in CST3 leads to the depo-
sition of amyloid fibrils in the blood vessels of the brain
and subsequently to multiple hemorrhages. HCHWA-I
is very similar to the Dutch type of HCHWA (HCHWA-
D), in which APP, rather than CST3, is the mutated locus
(Prelli et al. 1988). Both diseases, however, involve the
colocalization of both CST3 and amyloid-b in the cor-
tical blood vessels (Bornebroek et al. 1996; Maat-
Schieman et al. 1996; Wei et al. 1998).
Although it has been suggested that CST3 might be
involved in APP processing and/or generation of amy-
loid-b, the exact mechanism of biological interaction re-
mains to be determined. A high-affinity substrate of
CST3, cathepsin S, is known to cleave APP into deriv-
atives containing amyloid-b in vitro (Munger et al. 1995)
and to increase amyloid-b production in tissue culture
(Lemere et al. 1995). A separate line of investigation,
using transgenic mice, suggests that amyloid plaque in-
itiation is independent of CST3 levels but also that, once
plaques are formed, elevated CST3 levels are associated
with deposition of CST3 layers onto the amyloid plaque
cores (Steinhoff et al. 2001). Whatever the mechanism,
our results support the hypothesis that these two pro-
teins interact to affect susceptibility to or progression of
AD.
With the covariates we used, we were unable to detect
substantial linkage in two candidate regions: the PSEN2
region on chromosome 1 (Levy-Lehad et al. 1995) and
the LRP1 region on chromosome 12 (Pericak-Vance et
al. 1997). Covariates failed to significantly improve the
modest evidence for linkage to the HLA/TNF region on
chromosome 6 (Collins et al. 2000), to 10q21-22 (Myers
et al. 2000, Ertekin-Taner et al. 2000), or to the a2-
macroglobulin region on 12q13 (Blacker et al. 1998),
previously detected in part using these data.
More generally, it is of interest to compare our findings
with earlier genome results using the same data. Kehoe
et al. (1999) analyzed the whole sample (292 ASPs), a
subset without E4 alleles (63 ASPs), and a subset in
which both members had at least one E4 allele (162
ASPs). Their results were consistent with the analyses
shown in figure 1 and table 2, with some differences in
the relative magnitudes of linkage evidence at different
locations. In addition, because we formally tested for the
effect of E4 on linkage, we did not report as significant
some of the subgroup signals reported by Kehoe et al.
(1999). If we had used a more liberal significance cri-
terion, such as .01, we would have included some of
these signals, as well as additional E4 signals not re-
ported by Kehoe et al. (1999). Interestingly, Kehoe et al.
used exclusion mapping to eliminate regions at or near
the locations of our signal on chromosomes 20, using a
sibling recurrence-risk ratio of 1.4.
To summarize our key findings, we have described
evidence for the existence of a genetically identifiable
subtype of “late-onset” AD limited to the most elderly
and characterized, in these data, by joint linkage to 21p
and 20p. Our analysis suggests that the development
and/or rate of progression of AD in such families re-
quires the presence of high-risk alleles at both genes,
which likely interact biologically to increase disease risk.
We believe that this subtype of AD is biologically in-
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dependent of ApoE and that its association with E2 in
this data set is the result of E4-related attrition at earlier
ages. In addition, we have found some evidence that a
gene in the PSEN1 region contributes to a subtype of
AD found in families of earlier onset and in which E4
may play a more direct role.
Because of issues relating to multiple comparisons, we
view our analyses as exploratory; our results require
confirmation in an independent sample. Like Goddard
et al. (2001) and Olson et al. (2001), we note that the
ability to include covariates increases the overall prob-
ability of type I errors due to multiple analyses of the
same genetic data. In this report, we have used pointwise
significance levels associated with a single analysis. It is
likely, however, that complete accounting of multiple
comparisons in the context of a genome scan will require
prohibitively small significance levels. Further, we believe
that the presence of locus heterogeneity is the single
most-important impediment to the successful detection
and replication of baseline linkage results for complex
genetic disorders. Thus, failure to account for locus het-
erogeneity places a severe limitation on the rate of sci-
entific progress. A balance must therefore be struck be-
tween the need for timely gene discovery and the need
to be prudent. In general, we recommend careful prior
selection of covariates and cautious interpretation of
results.
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